As of Friday, February 27, Fulgent Genetics, Inc.’s FLGT share price has dipped by 31.34%, which has investors questioning if this is right time to buy.

Earl Kehrmeyer, 98, shares his journey from a small Dodge County farm to making an impact on the global genetics stage.

Being invited to present research at an international academic conference is an honor for any seasoned professional. But for ...

Beam Therapeutics Inc. buy thesis: base-editing gene therapy leaders, risto-cel & BEAM-302 catalysts, strong cash runway.

He kicked things off emphatically with a dominant Senior Bowl showing against upper echelon, NFL bound competition. Then at the Combine he was measured with class-leading 35” arms and an 85 ¾” ...

Beef-on-dairy has rapidly evolved into a major contributor to the U.S. beef supply, reshaping how dairy and beef sectors work together and positioning itself as a lasting force in the marketplace.

Even though the final game left a bitter taste in their mouths, the New England Patriots have plenty to feel good about coming out of the 2025 NFL season. Having won just eight total games the ...

Q4 2025 Earnings Call February 26, 2026 4:30 PM ESTCompany ParticipantsMike Brophy - Chief Financial OfficerSteve Chapman - CEO ...

“I was pretty sad and the world was feeling really cold and mean,” Magar, who earlier directed “Night Side Songs," “The Half-God of Rainfall,” “Macbeth In Stride" and "We Live in Cairo,” said at the ...

As of Thursday, February 26, Sarepta Therapeutics, Inc.’s SRPT share price has dipped by 12.49%, which has investors questioning if this is right time to buy.

(DecisionDx ®-Melanoma, TissueCypher ®) increased 37% over 2024. Exceeded 2025 guidance with full-year revenue of $344 milli ...

... Read more ...